PADCEV™ Plus KEYTRUDA™, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer
First and only combination regimen to improve survival when used before and after surgical cystectomy in cisplatin-ineligible patients…